Related references
Note: Only part of the references are listed.Age-based (<65 vs >= 65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
Kevin L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
Ilaria Bertoldi et al.
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Sairaj Satarker et al.
POSTGRADUATE MEDICINE (2021)
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
Arthur Kavanaugh et al.
JOURNAL OF RHEUMATOLOGY (2021)
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
Yusuke Miyazaki et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis
Chong-xiang Chen et al.
LEUKEMIA (2021)
The safety of JAK-1 inhibitors
Benjamin Clarke et al.
RHEUMATOLOGY (2021)
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Patricia O. Guimaraes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial
Vincent C. Marconi et al.
LANCET RESPIRATORY MEDICINE (2021)
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
Naoki Iwamoto et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
Hideto Kameda et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study
Leonard H. Calabrese et al.
ARTHRITIS CARE & RESEARCH (2020)
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
Victoria Furer et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib
Kevin L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
JAK Inhibitors: Prospects in Connective Tissue Diseases
Hanxiao You et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2020)
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis
Kevin L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial
Ronald van Vollenhoven et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Faping Wang et al.
MAYO CLINIC PROCEEDINGS (2020)
A review of upadacitinib in rheumatoid arthritis
Yoshiya Tanaka
MODERN RHEUMATOLOGY (2020)
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Stanley B. Cohen et al.
RMD OPEN (2020)
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
Ennio Giulio Favalli et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Baricitinib restrains the immune dysregulation in patients with severe COVID-19
Vincenzo Bronte et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
M. C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients
Emma Stevens et al.
ACR OPEN RHEUMATOLOGY (2020)
Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study
Ajinkya Pawar et al.
LANCET RHEUMATOLOGY (2020)
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
Josef S. Smolen et al.
LANCET (2019)
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
Katie Bechman et al.
RHEUMATOLOGY (2019)
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Roy M. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Mark C. Genovese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Clinical significance of Janus Kinase inhibitor selectivity
Ernest H. Choy
RHEUMATOLOGY (2019)
Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study
Bella Mehta et al.
RMD OPEN (2019)
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2019)
STAT5B: A Differential Regulator of the Life and Death of CD4+ Effector Memory T Cells
Sonia S. Majri et al.
JOURNAL OF IMMUNOLOGY (2018)
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Massimo Gadina et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Mark C. Genovese et al.
LANCET (2018)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R. Burmester et al.
LANCET (2018)
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Marina Amaral de Avila Machado et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
Ben Kluender et al.
CLINICAL PHARMACOKINETICS (2018)
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis
Yong Chen et al.
SCIENTIFIC REPORTS (2017)
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
Kevin L. Winthrop et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity
Alexander N. R. Weber et al.
FRONTIERS IN IMMUNOLOGY (2017)
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Mechanisms and consequences of Jak-STAT signaling in the immune system
Alejandro V. Villarino et al.
NATURE IMMUNOLOGY (2017)
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Kevin L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2016)
SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RA: AN INTEGRATED ANALYSIS
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
A. L. Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases Implications for Vaccination
Huifeng Yun et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination
T. Craig Cheetham et al.
MAYO CLINIC PROCEEDINGS (2015)
Risk of Disseminated Varicella Zoster in Immunosuppressed Patients Receiving Zoster Vaccination
Michael R. Bubb
MAYO CLINIC PROCEEDINGS (2015)
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Himal Lal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
Stanley Cohen et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Kevin L. Winthrop et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome
Gulbu Uzel et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
The influence of ageing on the development and management of rheumatoid arthritis
Annemieke M. H. Boots et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Joachim Listing et al.
RHEUMATOLOGY (2013)
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
James B. Galloway et al.
RHEUMATOLOGY (2011)
Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis
Diane Lacaille et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
The JAK-STAT signaling pathway: Input and output intergration
Peter J. Murray
JOURNAL OF IMMUNOLOGY (2007)
Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency
S Dupuis et al.
NATURE GENETICS (2003)
Signaling through the JAK/STAT pathway, recent advances and future challenges
T Kisseleva et al.
GENE (2002)
Share Paper
